August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substances−bumetanide, nicardipine hydrochloride, and vasopressin−on the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- Study: Excessive nurse overtime, agency staffing harm patients
- Commentary: Technology no substitute for cadaver-based medical education
- Study: Early-stage breast cancer surgery may not be necessary after chemo, radiation
- Experimental brain implant translates thoughts to speech
- Nurses deem flexible, transparent scheduling key to satisfaction, retention
- OR Manager 2025 Career/Salary Survey offers opportunities to learn, give back
- The Joint Commission revises volume criteria for cardiac, stroke certifications
- Pulse oximetry monitoring at home found to save lives of high-risk opioid surgery patients
- New data suggest same-day discharge is safe for joint replacement patients with atrial fibrillation
- FBI investigates as Oracle health data breach exposes patient information
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement